SUMMARY Lentiviral display platform engineered to directly select and enrich antibodies based on their ability to induce receptor-mediated endocytosis, thereby streamlining the discovery of highly internalizing candidates for targeted therapies The Unmet Need: Efficient discovery platforms that directly select internalizing antibodies for… Read More
SUMMARY Novel antibodies to rapidly and safely expand γδ T cells enabling large-scale production for cancer immunotherapies like γδ CAR-T cells, and potentially boosting these cells directly in patients The Unmet Need: Efficient large-scale expansion of γδ T cells with enhanced… Read More
SUMMARY Novel antibodies precisely targeting cancer cells by binding to the Prolactin Receptor (PRLR) to diagnose cancer, direct immune cells to destroy tumors, and inhibit cancer growth signals, without affecting healthy cells The Unmet Need: Novel antibodies to effectively modulate cancer cell… Read More
SUMMARY Antibodies that block growth hormone signaling by binding the receptor or hormone to stop receptor pairing, based on high-affinity, defined sequences for therapeutic and research use. The Unmet Need: Effective therapeutic strategies that can precisely and sustainably inhibit growth hormone receptor-mediated… Read More
SUMMARY Synthetic monoclonal antibodies using phage display to bind and block the human growth hormone receptor, potentially offering a more potent and specific treatment for conditions like acromegaly by inhibiting receptor activation and downstream signaling. The Unmet Need: Innovative approaches to develop… Read More
SUMMARY A panel of pan-specific Vγ9Vδ2 TCR-recognizing antibodies that allosterically trigger T-cell activation to engage and kill cancer cells, making it highly applicable for targeted cancer therapy. The Unmet Need: Strategy to safely and effectively harness Vγ9Vδ2 T cells for immunotherapeutic interventions… Read More
SUMMARY A novel antibody-drug conjugate (ADC) with a lactate-responsive linker, enhancing therapeutic specificity by remaining stable in healthy tissues and releasing its therapeutic payload in high lactate tumor environments. Unmet need: A highly specific cancer drug that selectively activates in the tumor microenvironment,… Read More
SUMMARY Engineered recombinant fusion of the dendritic cell growth factor Flt3L to serum albumin to modulate the antigen-presenting compartment and bias it toward tolerance particularly against therapeutic proteins. The Unmet Need: Novel technologies to modulate the immune system to induce tolerance against therapeutic proteins… Read More
SUMMARY Cell division is a fundamental biological process, ensured to be of high fidelity by the Chromosome Passenger Complex (CPC), a crucial protein complex involved in regulating various chromosomal and cytoskeletal activities. The CPC, composed of survivin, borealin, INCENP, and Aurora B kinase, governs essential cell division functions, including spindle… Read More
SUMMARY Detection and monitoring of autoantibodies against Angiotensin II in COVID-19 patients, guiding diagnosis, treatment, and vaccine design to reduce blood pressure complications and prevent harmful autoimmune responses linked to the virus’s Spike protein The Unmet Need: Novel strategies to understand… Read More
SUMMARY Traditionally, antibodies were produced using animal immunization methodologies. While this approach is still in broad use, recombinant display technologies have now assumed the leading role in producing antibody‐based affinity reagents. A particularly powerful aspect of these engineered reagents is that… Read More
SUMMARY CD73 is an ectonucleotidase tethered by a glycosylphosphatidyl anchor to the extracellular side of many cell types. Along with NTPDase-1 CD39, CD73 is an important regulator of a cells inflammatory response. Cell death/stress triggers release of ATP which activates pro-inflammatory and immunostimulatory cell pathways. ATP concentrations are decreased through… Read More